AndroGel Switching: Moving Between Testosterone Gel and Other TRT Formulations

How AndroGel Works: Mechanism and Pharmacokinetics

AndroGel delivers testosterone through the stratum corneum, bypassing first-pass hepatic metabolism. Once absorbed, testosterone acts as a pro-hormone: 5-alpha reductase converts a portion to dihydrotestosterone (DHT), and aromatase converts another portion to estradiol. Both metabolites are physiologically active.

Absorption and Serum Kinetics

After a single 5 g application of AndroGel 1%, approximately 10% of the applied dose is absorbed over 24 hours, yielding roughly 5 mg of systemic testosterone per packet [1]. Steady-state serum concentrations are reached by day 2 to 3 of daily application. The FDA-approved prescribing information confirms that serum testosterone levels return to pre-treatment baseline within 4 to 5 days of discontinuation [1].

DHT and Estradiol Conversion

Topical testosterone raises DHT more than intramuscular formulations do on a milligram-per-milligram basis. The FDA label for AndroGel 1% notes mean DHT levels approximately 2.5-fold above baseline at steady state, compared with a roughly 1.5-fold rise seen with testosterone cypionate injections [1]. Clinicians switching patients from gel to injection should expect a modest drop in serum DHT even when total testosterone is held constant. Estradiol trends generally track total testosterone across formulations, though individual aromatase activity varies widely [2].

Why Formulation Matters for Switching

Bioavailability differences between formulations mean that a simple milligram-for-milligram conversion does not exist. A man stable on 81 mg/day of AndroGel 1.62% absorbs a net systemic dose near 8 mg/day, while 200 mg of testosterone cypionate every two weeks delivers roughly 14 mg/day over the injection interval on average. Understanding these absorption dynamics prevents both under-dosing and over-dosing at the time of transition [3].

Switching FROM AndroGel to Other Formulations

AndroGel to Testosterone Cypionate or Enanthate (Intramuscular)

The most common reason patients switch from AndroGel to injections is inconsistent absorption or subtherapeutic serum levels. Skin hydration, body hair density, and application technique all affect gel absorption by up to 30% between individuals [2].

Practical conversion starting point. A patient stable on AndroGel 1.62% at 81 mg/day (the maximum labeled dose) typically requires testosterone cypionate 100 to 150 mg per week via intramuscular or subcutaneous injection to maintain a similar mean serum testosterone. The T-Trials cohort showed that daily topical testosterone raised mean serum testosterone from 234 ng/dL to 457 ng/dL across the 12-month intervention period [4]. Published injection pharmacokinetic data show that 100 mg weekly of testosterone cypionate produces a mean trough near 450 to 550 ng/dL depending on injection interval [3].

Transition timing. Stop AndroGel on day 1 and administer the first injection on the same day or the following morning. There is no clinically meaningful washout needed because the gel clears within 4 to 5 days and the injection will begin contributing to serum levels within 24 to 48 hours [1]. Recheck a morning total testosterone (trough, the day before the next injection) at 3 to 4 weeks.

AndroGel to Subcutaneous Testosterone Cypionate

Subcutaneous (SQ) delivery of testosterone cypionate at doses of 50 to 80 mg per week produces smoother serum curves than intramuscular injection and is associated with less post-injection pain [5]. For patients switching from gel specifically because of mood fluctuations tied to daily variation, SQ weekly or twice-weekly dosing at 50 to 70 mg per injection may provide more consistent trough-to-peak ratios. Monitor hematocrit at 6 to 12 weeks post-switch, as both formulations carry polycythemia risk.

AndroGel to Testosterone Pellets (Testopel)

Testopel pellets (75 mg each) are implanted subcutaneously in the hip or buttock and release testosterone over 3 to 6 months. The Endocrine Society's 2018 clinical practice guideline recommends pellet dosing in the range of 150 to 450 mg per implantation cycle, with re-implantation guided by serum testosterone measured at 3 months [6].

Timing the switch. Stop AndroGel 24 hours before pellet implantation. Because pellets begin releasing immediately, no bridge therapy is needed. Expect serum testosterone to peak at 4 to 6 weeks post-implantation, then taper gradually. Some men experience supraphysiologic levels early; a testosterone check at 4 weeks catches this.

AndroGel to Testosterone Nasal Gel (Natesto)

Natesto (testosterone nasal gel 5.5 mg per actuation) delivers testosterone via the nasal mucosa and requires three-times-daily dosing. Mean serum testosterone after Natesto 11 mg three times daily in the phase III trial reached 421 ng/dL, compared with the pre-treatment mean of 209 ng/dL [7]. Because Natesto does not affect the hypothalamic-pituitary-testicular axis as profoundly as other formulations, it is sometimes preferred by men who want to preserve fertility.

Switching protocol. Stop AndroGel on day 1 of Natesto initiation. Recheck testosterone within 2 to 3 weeks given Natesto's short half-life. If levels fall below 300 ng/dL at week 3, the dose can be adjusted within the labeled range.

AndroGel to Testosterone Undecanoate (Jatenzo, Tlando, Kyzatrex)

Oral testosterone undecanoate formulations are absorbed via lymphatic pathways, avoiding first-pass hepatic metabolism. The FDA approved Jatenzo in 2019 based on data showing 87% of men achieved mean total testosterone within the normal range (300 to 1,000 ng/dL) at 12 weeks [8]. Starting doses vary by product but Jatenzo begins at 237 mg twice daily with meals.

Stop AndroGel the morning the oral product begins. Fat content of meals drives absorption, so counsel patients to take oral testosterone undecanoate consistently with a moderate-fat or high-fat meal. Recheck testosterone at 3 to 4 weeks; titrate based on a level drawn 6 hours after the morning dose.

Switching TO AndroGel From Other Formulations

From Testosterone Cypionate/Enanthate Injections

Men moving from injections to AndroGel often cite injection fatigue, needle aversion, or a partner's concern about needle disposal. The serum testosterone half-life of testosterone cypionate is approximately 8 days [3], meaning meaningful concentrations persist for 2 to 3 weeks after the last injection.

Timing. Begin AndroGel 7 days after the last injection for weekly dosing protocols, or 14 days after the last injection for biweekly protocols. This prevents a period of combined supraphysiologic exposure. Start with 81 mg/day (two pumps of 1.62%) and recheck at 2 to 4 weeks, adjusting as needed.

From Testosterone Pellets

Pellets taper gradually, so the transition window is longer. Track serum testosterone monthly starting at month 3 post-implantation. When levels drop below 400 ng/dL, start AndroGel at 40.5 mg/day (one pump of 1.62%) and re-titrate. Beginning gel too early while pellet levels are still strong can drive testosterone above 1,000 ng/dL and raise hematocrit significantly [6].

From Testosterone Patches (Androderm)

Androderm delivers 2 to 4 mg of testosterone per 24-hour patch. Transition is straightforward: discontinue the patch in the morning and begin AndroGel the following morning. No washout is needed because both are transdermal systems with similar clearance kinetics. Start with a dose of AndroGel that approximates the same daily delivery: 2 mg patch corresponds to roughly 40.5 mg/day of AndroGel 1.62%.

From Oral Testosterone Undecanoate

Oral testosterone undecanoate clears within 24 hours of the last dose due to its short half-life [8]. Stop the oral product in the evening; begin AndroGel the next morning. Straightforward transition, but watch for a dip in levels during the first week as steady-state gel absorption builds over 2 to 3 days.

Monitoring After Any Switch

The table below outlines the HealthRX monitoring framework used across all formulation switches. This framework synthesizes the Endocrine Society 2018 guideline recommendations with pharmacokinetic data from the formulations discussed above.

| Timepoint | Labs to Check | Clinical Notes | |-----------|---------------|----------------| | Week 2 to 4 | Total testosterone (morning, trough for injections) | Confirm therapeutic range 400 to 700 ng/dL for most men | | Week 6 to 12 | Total T, free T, hematocrit, PSA | Rule out polycythemia (hematocrit above 54%) | | Month 6 | Total T, free T, LH, FSH, hematocrit, lipid panel | Assess HPTA suppression, cardiovascular markers | | Month 12 | All of above plus bone density if baseline was low | Confirm sustained response or adjust formulation again |

The Endocrine Society guideline states: "We recommend monitoring testosterone levels 3 to 6 months after starting treatment and then annually." [6] Stricter monitoring at 2 to 4 weeks during a formulation switch is a supplement to, not a replacement for, this annual schedule.

Hematocrit Management

Polycythemia is a class-wide risk, not formulation-specific. A 2020 review in the Journal of Clinical Endocrinology and Metabolism found that hematocrit exceeded 54% in approximately 8% of men on testosterone therapy, with injectable formulations carrying a slightly higher rate than topical formulations due to higher peak-to-trough ratios [9]. When switching from gel to injection, recheck hematocrit at 6 weeks because the injection's higher peak testosterone may push red cell mass upward faster than the gel did.

PSA Monitoring

The FDA prescribing information for AndroGel includes a warning to monitor PSA before initiating therapy and at 3 to 6 months. Switching formulations does not reset this timeline. If a man is 12 months into TRT on injections and switches to AndroGel, his next PSA check follows the established annual schedule unless his PSA has risen more than 1.4 ng/mL above baseline, which warrants urologic evaluation regardless of formulation [6].

Transfer Risk With Topical Gel

Testosterone gel transfers to skin contacts. The FDA has documented cases of secondary exposure in women and children who had direct skin contact with a gel-using man [1]. Men switching to AndroGel from a non-topical formulation must be counseled to cover the application site with clothing after the gel dries (about 5 minutes), to wash hands thoroughly, and to shower before close skin contact.

Special Populations and Considerations

Men Over 65

The T-Trials, published in the New England Journal of Medicine in 2016 (N=788, mean age 72), randomized hypogonadal older men to testosterone gel or placebo for 12 months. The testosterone group achieved a mean serum testosterone of 457 ng/dL vs. 232 ng/dL in the placebo group (P<0.001), with improvements in sexual function and bone mineral density but no statistically significant cardiovascular benefit at 12 months [4]. Older men switching between formulations may have slower skin absorption due to thinner dermis; this can favor injectable formulations if gel levels are consistently subtherapeutic.

Men Desiring Fertility Preservation

All exogenous testosterone suppresses LH and FSH, reducing sperm production. Men who want to preserve fertility should not switch to AndroGel or any other exogenous testosterone; instead, they should discuss human chorionic gonadotropin (hCG) therapy or clomiphene citrate with a reproductive endocrinologist. The American Society for Reproductive Medicine notes that testosterone therapy is contraindicated in men seeking fertility [10].

Cardiovascular Risk

The 2023 TRAVERSE trial (N=5,246 men with hypogonadism and high cardiovascular risk, mean follow-up 33 months) found no significant difference in major adverse cardiovascular events between testosterone and placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [11]. The trial used a topical testosterone gel, making this data directly applicable to AndroGel users. Men switching from injections to gel for cardiovascular reasons can reference this trial, though it does not prove superiority of gel over injection for cardiac endpoints.

Cost, Insurance, and Practical Barriers to Switching

AndroGel brand-name pricing runs approximately $500 to $600 per month without insurance. Generic testosterone gel 1.62% is available for as low as $40 to $80 per month at major pharmacy chains. Testosterone cypionate generic vials cost under $30 for a 10 mL multi-dose vial, making injections the lowest-cost option by a wide margin [12].

Insurance prior authorization requirements often drive switching decisions. If a plan covers injections but not branded AndroGel, generic testosterone gel is the appropriate cost-equivalent bridge. Clinicians should document two failed formulations and a medical rationale (for example, documented skin absorption failure with gel, confirmed by subtherapeutic serum levels) when requesting prior authorization for pellets or oral undecanoate, which carry higher price points.